The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Open accessAbstract
Objective: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods: Amyloid‐β 1 to 42 peptide (Aβ 1–42), total tau (t‐tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy‐confirmed AD cases and 52 age‐matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t‐tau and Aβ 1–42 in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy‐confirmed CSF data. Results: CSF Aβ 1–42 was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for Aβ 1–42, t‐tau, and APO ε 4 allele count provided the best assessment delineation of mild AD. An AD‐like baseline CSF profile for t‐tau/Aβ 1–42 was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. Interpretation: The CSF biomarker signature of AD defined by Aβ 1–42 and t‐tau in the autopsy‐confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD. Ann Neurol 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased concentrations of extracellular soluble phosphorylated tau (p-tau) and total tau (t-tau) constitute a reliable index of this intracellular process in mild cognitive impairment due to AD2,3 and AD dementia.2,4”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Abnormal CSF Aβ42 values were defined using the previously established cut-off of <192 ng/L57–59.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationMueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 719
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/S1474-4422(03)00530-1 · DOI · Paper page
Cited by
Sorted by citations
Items 701–800 of 1,012
Marshall, G. A., Initiative, A. D. N., Lorius, N., Locascio, J. J., Hyman, B. T., Rentz, D. M., Johnson, K. A., & Sperling, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132768 · Cited by 52
Self-citationThe plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease
Vanmierlo, T., Popp, J., Kölsch, H., Friedrichs, S., Jessen, F., Stoffel‐Wagner, B., Bertsch, T., Hartmann, T., Maier, W., von Bergmann, K., et al. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01713.x · Cited by 49
Initiative, A. D. N., Liu, Y., Tan, L., Wang, H.-F., Liu, Y., Hao, X., Tan, C., Jiang, T., Liu, B., Zhang, D., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9388-7 · Cited by 54
Self-citationMoore, D. W., Kovanlıkaya, İ., Heier, L., Raj, A., Huang, C. C., Chu, K.-W., & Relkin, N. R. (2011) · Neurology Research International · doi:10.1155/2012/718150 · Cited by 50
Morinaga, A., Ono, K., Ikeda, T., Ikeda, Y., Shima, K., Noguchi‐Shinohara, M., Samuraki, M., Yanase, D., Yoshita, M., Iwasa, K., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000320265 · Cited by 56
Cerebrospinal fluid and blood biomarkers in Alzheimer’s disease
Humpel, C. (2011) · World Journal of Psychiatry · doi:10.5498/wjp.v1.i1.8 · Cited by 54
Ye, B. S., Lee, W., Ham, J. H., Lee, J. J., Lee, P. H., Sohn, Y. H., & Initiative, T. A. D. N. (2016) · European Journal of Neurology · doi:10.1111/ene.12969 · Cited by 51
Benussi, A., Alberici, A., Ferrari, C., Cantoni, V., Dell’Era, V., Turrone, R., Cotelli, M. S., Binetti, G. G., Paghera, B., Koch, G., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0423-6 · Cited by 50
Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia
Initiative, A. D. N., Tan, M., Xi, J., Li, J., Xu, W., Wang, H.-F., Tan, C., Dong, Q., Zuo, C., Tan, L., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00621-6 · Cited by 52
Self-citationAssociation of amyloid-β CSF/PET discordance and tau load 5 years later
Reimand, J., Collij, L. E., Scheltens, P., Bouwman, F. H., Ossenkoppele, R., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010739 · Cited by 50
Self-citationBubu, O. M., Umasabor‐Bubu, O. Q., Turner, A. D., Parekh, A., Mullins, A. E., Kam, K., Birckbichler, M. K., Mukhtar, F., Mbah, A. K., Williams, N. J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12184 · Cited by 57
Self-citationStructural Changes in Thalamic Nuclei Across Prodromal and Clinical Alzheimer’s Disease
Bernstein, A. S., Initiative, T. A. D. N., Rapcsak, S. Z., Hornberger, M., & Saranathan, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201583 · Cited by 50
Scales as outcome measures for Alzheimer's disease
Black, R. S., Greenberg, B., Ryan, J. M., Posner, H. B., Seeburger, J. L., Amatniek, J. C., Resnick, M., Mohs, R. C., Miller, D. S., Saumier, D., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.667 · Cited by 50
Dkk‐3 is elevated in CSF and plasma of Alzheimer’s disease patients
Zenzmaier, C., Marksteiner, J., Kiefer, A., Berger, P., & Humpel, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06158.x · Cited by 49
Borkowski, K., Pedersen, T. L., Seyfried, N. T., Lah, J. J., Levey, A. I., Hales, C. M., Dammer, E. B., Blach, C., Louie, G., Kaddurah‐Daouk, R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00893-6 · Cited by 50
Timsina, J., Ali, M., Do, A. N., Wang, L., Western, D., Sung, Y. J., & Cruchaga, C. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106373 · Cited by 48
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 57
Discriminative multi-task feature selection for multi-modality classification of Alzheimer’s disease
Initiative, T. A. D. N., Ye, T., Zu, C., Jie, B., Shen, D. G., & Zhang, D. (2015) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9437-x · Cited by 49
Alzheimer’s Disease, Anesthesia, and Surgery: A Clinically Focused Review
Berger, M., Burke, J. R., Eckenhoff, R. G., & Mathew, J. P. (2014) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2014.04.014 · Cited by 49
Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI
Toledo, J. B., Da, X., Bhatt, P., Wolk, D. A., Arnold, S. E., Shaw, L. M. J., Trojanowski, J. Q., Davatzikos, C. A., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055531 · Cited by 49
Self-citationEffects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults
Mattsson, N., Insel, P. S., Nosheny, R. L., Trojanowski, J. Q., Shaw, L. M. J., Jack, C. R., Tosun, D., & Weiner, M. W. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.027 · Cited by 49
Self-citationLessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
Mattsson, N., Zetterberg, H., & Blennow, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/610613 · Cited by 50
Self-citationQin, J., Jo, D., Cho, M., & Lee, Y. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.04.061 · Cited by 49
Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases
Seino, Y., Nakamura, T., Kawarabayashi, T., Hirohata, M., Narita, S., Wakasaya, Y., Kaito, K., Ueda, T., Harigaya, Y., & Shoji, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181152 · Cited by 50
Serum and brain natural copper stable isotopes in a mouse model of Alzheimer’s disease
Moynier, F., Creech, J., Dallas, J., & Borgne, M. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47790-5 · Cited by 50
Soluble TREM2 and Inflammatory Proteins in Alzheimer’s Disease Cerebrospinal Fluid
Rauchmann, B., Sadlon, A., Perneczky, R., & Initiative, A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191120 · Cited by 49
Self-citationExtracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis
Yuyama, K., Sun, H., Fujii, R., Hemmi, I., Ueda, K., & Igeta, Y. (2024) · Brain · doi:10.1093/brain/awad361 · Cited by 47
Neuroimaging Results Impose New Views on Alzheimer’s Disease—the Role of Amyloid Revised
Fjell, A. M., & Walhovd, K. B. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8228-7 · Cited by 48
Amlien, I. K., Fjell, A. M., Walhovd, K. B., Selnes, P., Stenset, V. T. V., Grambaitė, R., Bjørnerud, A., Due‐Tønnessen, P., Skinningsrud, A., Gjerstad, L., et al. (2012) · Radiology · doi:10.1148/radiol.12120319 · Cited by 48
Deficient neurotrophic factors of CSPG4‐type neural cell exosomes in Alzheimer disease
Goetzl, E. J., Nogueras‐Ortiz, C. J., Mustapić, M., Mullins, R. J., Abner, E. L., Schwartz, J. B., & Kapogiannis, D. (2018) · The FASEB Journal · doi:10.1096/fj.201801001 · Cited by 48
Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer’s disease
Phillips, J. S., Re, F. D., Irwin, D. J., McMillan, C. T., Vaishnavi, S., Xie, S. X., Lee, E. B., Cook, P. A., Gee, J. C., Shaw, L. M. J., et al. (2019) · Brain · doi:10.1093/brain/awz091 · Cited by 51
Self-citationTsai, C., Liang, C., Lee, J., Su, M., Lin, C., Chu, H., Tsai, C., Lin, G., Lin, Y., & Yang, F. (2019) · Journal of Clinical Medicine · doi:10.2139/ssrn.3464407 · Cited by 48
Time between milestone events in the Alzheimer's disease amyloid cascade
Insel, P. S., Donohue, M., Berron, D., Hansson, O., & Mattsson, N. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117676 · Cited by 50
Hippocampal Proton MR Spectroscopy in Early Alzheimer’s Disease and Mild Cognitive Impairment
Foy, C. M. L., Daly, E., Glover, A., Tuura, R., Simmons, A., Murphy, D., & Lovestone, S. (2011) · Brain Topography · doi:10.1007/s10548-011-0170-5 · Cited by 48
Li, K., O'Brien, R., Lutz, M., Luo, S., & Initiative, T. A. D. N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.004 · Cited by 44
Clinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Frontobasal gray matter loss is associated with the TREM2 p.R47H variant
Luis, E. O., Ortega-Cubero, S., Lamet, I., Razquin, C., Cruchaga, C., Benitez, B. A., Lorenzo, E., Irigoyen, J., Pastor, M. A., & Pastor, P. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.007 · Cited by 47
Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up
Niemantsverdriet, E., Feyen, B. F. E., Bastard, N. L., Martin, J., Goeman, J., Deyn, P. P. D., & Engelborghs, S. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142103 · Cited by 47
Tariciotti, L., Casadei, M., Honig, L. S., Teich, A. F., McKhann, G. M., Tosto, G., & Mayeux, R. P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180548 · Cited by 46
Early- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?
Valdez-Gaxiola, C. A., Rosales-Leycegui, F., Gaxiola-Rubio, A., Moreno-Ortíz, J. M., & Figuera, L. E. (2024) · Diseases · doi:10.3390/diseases12060110 · Cited by 55
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, M. W., Kanoria, S., Miller, M. J., Aisen, P. S. S., Beckett, L. A., Conti, C., Diaz, A., Flenniken, D., Green, R. C., Harvey, D. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14321 · Cited by 54
Self-citationLeung, Y. Y., Toledo, J. B., Nefedov, A., Robi Polikar, A., Raghavan, N., Xie, S. X., Farnum, M. A., Schultz, T., Baek, Y., Deerlin, V. M. V., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.06.008 · Cited by 49
Self-citationMemory, executive, and multidomain subtle cognitive impairment
Toledo, J. B., Bjerke, M., Chen, K., Rozycki, M., Jack, C. R., Weiner, M. W., Arnold, S. E., Reiman, E. M., Davatzikos, C. A., Shaw, L. M. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001738 · Cited by 48
Self-citationNo Diagnostic Value of Plasma Clusterin in Alzheimer's Disease
Silajdžić, E., Minthon, L., Björkqvist, M., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050237 · Cited by 49
Savica, R., & Petersen, R. C. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.11.006 · Cited by 51
Self-citationMultimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load
Grothe, M. J., Villeneuve, S., Dyrba, M., Bartrés‐Faz, D., Wirth, M., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003585 · Cited by 47
Self-citationPrognosis and Diagnosis of Parkinson's Disease Using Multi-Task Learning
Emrani, S., McGuirk, A. M., & Xiao, W. (2017) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/3097983.3098065 · Cited by 47
Jan, A. T., Azam, M., Rahman, S., Almigeiti, A. M. S., Choi, D. H., Lee, E. J., Haq, Q. M. R., & Choi, I. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00356 · Cited by 49
Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases
Shimizu, S., Hirose, D., Hatanaka, H., Takenoshita, N., Kaneko, Y., Ogawa, Y., Sakurai, H., & Hanyu, H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00265 · Cited by 52
Kim, S. H., Yang, J. S., Lee, J. C., Lee, J.-Y., Lee, J., Kim, E., & Moon, M. H. (2018) · Journal of Chromatography A · doi:10.1016/j.chroma.2018.07.018 · Cited by 47
Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46
Self-citationHoward, E., Irwin, D. J., Rascovsky, K., Nevler, N., Shellikeri, S., Tropea, T. F., Spindler, M., Deik, A., Chen-Plotkin, A., Siderowf, A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011699 · Cited by 47
Self-citationCure, S., Abrams, K. R., Belger, M. A., Dell’Agnello, G., & Happich, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131559 · Cited by 47
Zhang, L., Du, X., Su, Y., Niu, S., Li, Y., Liang, X., & Luo, H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01111-z · Cited by 47
Tau is reduced in AD plasma and validation of employed ELISA methods.
Sparks, D. L., Kryscio, R. J., Sabbagh, M. N., Ziolkowski, C. H. J., Lin, Y., Sparks, L. M., Liebsack, C., & Johnson‐Traver, S. (2012) · Europe PMC (PubMed Central) · Cited by 45
Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers
Lehmann, M., Koedam, E., Barnes, J., Bartlett, J. W., Barkhof, F., Wattjes, M. P., Schott, J. M., Scheltens, P., & Fox, N. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.010 · Cited by 49
Ferreira, D., Rivero‐Santana, A., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00287 · Cited by 48
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 48
Escudero, J., Zajicek, J., & Ifeachor, E. (2011) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2011.6091597 · Cited by 46
Racine, A., Brickhouse, M., Wolk, D., & Dickerson, B. (2018) · Alzheimer's & Dementia · doi:10.1016/j.dadm.2018.02.007 · Cited by 48
Self-citationUdeh‐Momoh, C. T., Initiative, A. D. N., Su, B., Evans, S., Zheng, B., Sindi, S., Tzoulaki, I., Perneczky, R., & Middleton, L. T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181030 · Cited by 48
Self-citationPredicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls
Mattsson, N., Insel, P. S., Donohue, M., Jagust, W., Sperling, R., Aisen, P., & Weiner, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4530 · Cited by 45
Self-citationSex influences the effects of APOE genotype and Alzheimer’s diagnosis on neuropathology and memory
Duarte‐Guterman, P., Albert, A., Barha, C. K., Galea, L. A. M., & Initiative, O. B. O. T. A. D. N. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105248 · Cited by 48
Soluble Amyloid-β Consumption in Alzheimer’s Disease
Espay, A. J., Sturchio, A., Schneider, L. S., & Ezzat, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210415 · Cited by 46
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status
Swaminathan, S., Risacher, S. L., Yoder, K. K., West, J. D., Shen, L., Kim, S., Inlow, M. H., Foroud, T., Jagust, W., Koeppe, R. A., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.007 · Cited by 45
Self-citationPaterson, R. W., Bartlett, J. W., Blennow, K., Fox, N. C., Initiative, A. D. N., Shaw, L. M. J., Trojanowski, J. Q., Zetterberg, H., & Schott, J. M. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.58 · Cited by 45
Self-citationFlood, D. G., Marek, G. J., & Williams, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.021 · Cited by 46
Cerebrospinal Fluid Aβ and Tau Level Fluctuation in an Older Clinical Cohort
Moghekar, A. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.732 · Cited by 46
CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease
Initiative, A. D. N., Hu, W. T., Watts, K. D., Tailor, P. D., Nguyen, T. P., Howell, J. C., Lee, R. C., Seyfried, N. T., Gearing, M., Hales, C. M., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0277-8 · Cited by 45
Self-citationAccelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology
Insel, P. S., Mattsson, N., Mackin, R. S., Schöll, M., Nosheny, R. L., Tosun, D., Donohue, M., Aisen, P. S. S., Jagust, W., Weiner, M. W., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002683 · Cited by 46
Self-citationEnrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration
Wolz, R., Schwarz, A. J., Gray, K. R., Yu, P., Hill, D., & Initiative, A. D. N. (2016) · Neurology · doi:10.1212/wnl.0000000000003126 · Cited by 46
Self-citationSpoken language biomarkers for detecting cognitive impairment
Alhanai, T., Au, R., & Glass, J. R. (2017) · IEEE Workshop on Automatic Speech Recognition and Understanding (ASRU) · doi:10.1109/asru.2017.8268965 · Cited by 45
Schmitz, T. W., Soreq, H., Poirier, J., & Spreng, R. N. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1184-19.2019 · Cited by 47
APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer's disease
Lin, A., Parikh, I. J., Yanckello, L. M., White, R. S., Hartz, A. M. S., Taylor, C. E., McCulloch, S. D., Thalman, S. W., Xia, M., McCarty, K. L., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104834 · Cited by 45
Defining and predicting transdiagnostic categories of neurodegenerative disease
Cornblath, E. J., Robinson, J. L., Irwin, D. J., Lee, E. B., Lee, V. M. ‐., Trojanowski, J. Q., & Bassett, D. S. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0593-y · Cited by 48
Self-citationBanning, L. C. P., Ramakers, I. H. G. B., Rosenberg, P. B., Lyketsos, C. G., Leoutsakos, J., & Initiative, A. D. N. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5418 · Cited by 46
Self-citationNagata, T., Kobayashi, N., Shinagawa, S., Yamada, H., Kondo, K., & Nakayama, K. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1121-y · Cited by 46
Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures
Apostolova, L. G., Hwang, K., Avila, D., Elashoff, D. A., Omid Kohannim, A., Teng, E., Sokolow, S., Jack, C. R., Jagust, W., Shaw, L. M. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001231 · Cited by 45
Self-citationDeveloping a national strategy to prevent dementia: Leon Thal Symposium 2009
Khachaturian, Z. S., Barnes, D. E., Einstein, R., Johnson, S. C., Lee, V., Roses, A. D., Sager, M. A., Shankle, W. R., Snyder, P. J., Petersen, R. C., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.01.008 · Cited by 44
Self-citationAtrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials
Andrews, K. A., Marc Modat, A., Macdonald, K. E., Yeatman, T., Cardoso, M. J., Leung, K. K., Barnes, J., Villemagne, V. L., Rowe, C. C., Fox, N. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058816 · Cited by 48
Li, G., Millard, S. P., Peskind, E. R., Zhang, J., Yu, C., Leverenz, J. B., Mayer, C. L., Shofer, J., Raskind, M. A., Quinn, J. F., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.445 · Cited by 45
Schneider, L. S. S., Kennedy, R., Cutter, G., & Initiative, A. D. N. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.07.004 · Cited by 44
Self-citationZeng, K., Wang, Y., Ouyang, G., Bian, Z., Wang, L., & Li, X. (2015) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2015.00133 · Cited by 46
Moon, B., Kim, S., Park, Y. H., Lim, J., Youn, Y. C., Kim, S., Jang, J., & Initiative, A. D. N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170225 · Cited by 44
Self-citationGibbons, G. S., Kim, S., Robinson, J. L., Changolkar, L. N., Irwin, D. J., Shaw, L. M. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0687-5 · Cited by 44
Self-citationKey inflammatory pathway activations in the MCI stage of Alzheimer’s disease
Pillai, J. A., Maxwell, S., Bena, J., Bekris, L. M., Rao, S. M., Chance, M. R., Lamb, B. T., Leverenz, J. B., & Initiative, A. D. N. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50827 · Cited by 44
Self-citationBiomarker‐Responsive Nanosystems for Chronic Disease Theranostics
Fu, Q., Yu, L., Wang, Y., Li, P., & Song, J. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202206300 · Cited by 43
Matsumura, K., Ono, M., Kitada, A., Watanabe, H., Yoshimura, M., Iikuni, S., Kimura, H., Okamoto, Y., Ihara, M., & Saji, H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00440 · Cited by 43
Dowling, N. M., Johnson, S. C., Gleason, C. E., & Jagust, W. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.10.050 · Cited by 43
Stomrud, E., Minthon, L., Zetterberg, H., Blennow, K., & Hansson, O. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.002 · Cited by 43
Self-citationRusso, M. J., Campos, J., Vázquez, S., Sevlever, G. E., Allegri, R., & Initiative, T. A. D. N. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00046 · Cited by 45
Bonham, L. W., Geier, E. G., Steele, N. Z. R., Holland, D., Miller, B. L., Dale, A. M., Desikan, R. S., Yokoyama, J. S., & Initiative, A. D. N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00476 · Cited by 43
Self-citationGray matter structural covariance networks changes along the Alzheimer's disease continuum
Li, K., Luo, X., Zeng, Q., Huang, P., Shen, Z., Xu, X., Xu, J., Wang, C., Zhou, J., & Zhang, M. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101828 · Cited by 42
Rami, L., Solé‐Padullés, C., Fortea, J., Bosch, B., Lladó, A., Antonell, A., Olives, J., Castellvı́, M., Bartrés‐Faz, D., Sánchez‐Valle, R., et al. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2696 · Cited by 45
Cerebrospinal fluid α‐synuclein contributes to the differential diagnosis of Alzheimer's disease
Shi, M., Tang, L., Toledo, J. B., Ginghina, C., Wang, H., Aro, P., Jensen, P. H., Weintraub, D., Chen‐Plotkin, A. S., Irwin, D. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.015 · Cited by 42
Self-citationBiomarkers in frontotemporal lobar degenerations—Progress and challenges
Hu, W. T., Trojanowski, J. Q., & Shaw, L. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.012 · Cited by 42
Self-citationLeuzy, A., Mattsson, N., Cullen, N. C., Stomrud, E., Palmqvist, S., Joie, R. L., Iaccarino, L., Zetterberg, H., Rabinovici, G. D., Blennow, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12897 · Cited by 46
Self-citationAlzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Llado-Saz, S., Atienza, M., & Cantero, J. L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.023 · Cited by 43
Leuzy, A., Carter, S. F., Chiotis, K., Almkvist, O., Wall, A. E., & Nordberg, A. K. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142952 · Cited by 44
Metadata
- Authors
- Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M. ‐., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- University of Pennsylvania (US)
- Fujirebio (Belgium) (BE)
- University of California San Diego (US)
- Mayo Clinic (US)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Eli Lilly (United States) (US)
- Corresponding author
- Shaw, Leslie M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 65
- Issue
- 4
- Pages
- 403-413
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2696350
- OpenAlex
- W2008301592
- Cited by
- 2,065
- References
- 31
- Citations by year
- 2026: 59 · 2025: 82 · 2024: 110 · 2023: 89 · 2022: 114 · 2021: 125 · 2020: 136 · 2019: 141 · 2018: 129 · 2017: 135 · 2016: 121 · 2015: 146 · 2014: 131 · 2013: 130 · 2012: 136
- FWCI
- 85.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, AG 024904, P30AG010124, AG-10124, U19AG010483, U19AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, mild cognitive impairment, conversion to Alzheimer's disease, APOE ε4, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Diagnostic Imaging, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Threonine, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Statistics, Nonparametric, Area Under Curve, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
